TrialBlood advances2023

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.

Jad Othman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.